Rankings
▼
Calendar
ICCC
ImmuCell Corporation
$60M
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$14M
+24.9% YoY
Gross Profit
$7M
49.1% margin
Operating Income
-$954,000
-7.0% margin
Net Income
-$1M
-9.4% margin
EPS (Diluted)
$-0.19
Cash Flow
Operating Cash Flow
$233,511
Free Cash Flow
-$1M
Stock-Based Comp.
$313,144
Balance Sheet
Total Assets
$39M
Total Liabilities
$10M
Stockholders' Equity
$29M
Cash & Equivalents
$6M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$14M
$11M
+24.9%
Gross Profit
$7M
$5M
+29.8%
Operating Income
-$954,000
-$1M
+34.1%
Net Income
-$1M
-$2M
+44.2%
← Q4 2018
All Quarters
Q1 2019 →
ICCC FY 2019 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena